Asia Pacific's Psychedelic Medicine & Mental Health Conference
MELBOURNE - AUSTRALIA | 19–20 MARCH 2027
The future of psychedelic medicine is moving from research into practice.
TICKETS
Now available — early bird pricing.
Secure your place at PRS27. Tickets are now available for Australia's Psychedelic Medicine & Mental Health Symposium, taking place in Melbourne on 19–20 March 2027.
Standard
$495 AUD early bird
Full price $695
Student
$295 AUD early bird
Full price $395
VIP
$995 AUD early bird
Full price $1,495
Includes VIP dinner
Early bird offer expires 30 October 2027 or until sold out.
ONE ROOM. THE ENTIRE ASIA PACIFIC PSYCHEDELIC MEDICINE ECOSYSTEM.
PRS27 is designed as a high level meeting point for the emerging psychedelic medicine ecosystem. The symposium brings together people working across different parts of the sector because the future of psychedelic medicine will not be built by one profession, one discipline or one organisation.
Clinicians & Researchers
Educators & Trainers
Regulators & Policymakers
Healthcare Organisations
Biotech Companies
Investors
Practitioners
Patients & Communities
WHY PRS27?
Psychedelic medicine is entering a new phase.
The conversation is changing. For years, much of the psychedelic field was focused on whether these therapies could work. The next questions are increasingly practical:
How will they be delivered?
Who will deliver them?
How should practitioners be trained?
What does safe and effective clinical implementation look like?
How should governments and regulators respond?
What healthcare models can support psychedelic-assisted therapies?
Where will investment create the greatest impact?
How do we build a sustainable workforce?
What happens when psychedelic medicine becomes part of mainstream mental healthcare?
PRS27 is built around these questions.
THE PRS27 PROGRAMME
Two days exploring the future of psychedelic medicine.
The programme combines keynote presentations, expert roundtables, panel discussions, practical perspectives and networking. Rather than focusing exclusively on scientific research, PRS27 takes a broader view of the ecosystem required to translate psychedelic medicine into practice.
Clinical Practice
Emerging models of care, patient pathways, treatment protocols, clinical governance and implementation.
Psychiatry & Mental Health
The evolving role of psychedelic therapies within psychiatry and mental healthcare.
Research & Evidence
Clinical trials, translational research, emerging therapeutic models and evidence gaps.
Practitioner Training & Education
Workforce landscape, professional standards, supervision and competencies.
Regulation & Policy
Australia's regulatory environment, authorised prescribing pathways and governance.
Healthcare Delivery
Models for clinics, hospitals, telehealth and integrated mental healthcare.
Biotechnology & Innovation
Drug development, novel compounds, digital health and treatment platforms.
Investment & Capital
Investment trends, commercialisation, emerging business models and funding.
Ethics & Governance
Informed consent, patient safety, therapeutic boundaries and equity.
The Future of the Sector
What will psychedelic medicine look like in five, ten or twenty years?
WHO SHOULD ATTEND?
PRS27 is designed for people working across the psychedelic medicine and mental health ecosystem.
Psychiatrists
Stay ahead of the rapidly changing clinical, regulatory and professional landscape surrounding psychedelic-assisted therapies.
Psychologists & Psychotherapists
Explore emerging treatment models, practitioner education, clinical implementation and the future role of psychedelic-assisted therapy.
Researchers & Academics
Connect with clinicians, industry, investors and organisations translating psychedelic research into real-world applications.
Healthcare Professionals
Understand how psychedelic medicine may intersect with the future delivery of mental healthcare.
Clinic & Healthcare Operators
Explore emerging models for delivering psychedelic-assisted therapies and the infrastructure required.
Educators & Training Organisations
Understand the emerging workforce requirements and opportunities for practitioner education.
Pharmaceutical & Biotechnology Companies
Connect with the clinical, commercial and healthcare ecosystem surrounding psychedelic medicine.
Investors
Meet founders, clinicians, researchers and healthcare leaders and gain insight into emerging opportunities.
Regulatory, Policy & Government Professionals
Engage directly with the people developing and implementing the next generation of psychedelic medicine.
Entrepreneurs & Industry Leaders
Build relationships across the ecosystem and identify opportunities for collaboration, innovation and growth.
WHAT YOU'LL TAKE AWAY
PRS27 is designed to be practical, commercially relevant and clinically informed.
Clinical Landscape Clarity
Understand where psychedelic therapies are moving and what emerging clinical models may look like.
Regulatory Understanding
Explore the Australian regulatory environment and international developments shaping access.
Practitioner Training Insights
Understand the workforce challenge and what the future psychedelic therapy workforce may require.
Healthcare Delivery Perspectives
Explore how psychedelic therapies could be integrated into real-world healthcare systems.
Investment Intelligence
Understand where capital, innovation and commercial opportunities are emerging.
New Professional Connections
Meet clinicians, researchers, healthcare operators, investors, founders, educators and other sector leaders.
A View of What Comes Next
PRS27 is designed to help attendees understand not just where the sector is today, but where it is heading.
THE ROUNDTABLE FORMAT
Less conference. More conversation.
PRS27 is built around meaningful discussion. The symposium combines presentations with roundtables and moderated panels designed to bring different perspectives into the same room. The objective is not simply to deliver presentations, it is to create conversations between people who do not always have the opportunity to sit together.
Clinicians ↔ Investors
Researchers ↔ Healthcare Operators
Educators ↔ Practitioners
Industry ↔ Policymakers
Founders ↔ Partners
PRS27 is where those conversations happen.
delegates
Intentionally focused. Not a mass-market conference.
19–20 MARCH 2027
Start the conversation on Friday. Go deeper on Saturday.
Melbourne, Australia
PRS27 begins on Friday 19 March with afternoon registration and an opening networking event, before the main symposium takes place on Saturday 20 March. The main programme concludes with continued networking, followed by an exclusive VIP dinner on the evening of 20 March.
19 MARCH — REGISTRATION + OPENING NETWORKING
Afternoon: Registration opens and delegates arrive for PRS27.
Late Afternoon / Early Evening: Opening Networking Event — an opportunity to meet fellow delegates, speakers, clinicians, researchers, investors, healthcare leaders and industry representatives before the main symposium. A relaxed start to the PRS27 experience.
20 MARCH — THE MAIN PRS27 SYMPOSIUM
A full day examining the clinical, professional, regulatory and commercial forces shaping the future of psychedelic medicine.
- Morning: Keynotes, clinical perspectives and conversations examining the current state of psychedelic medicine.
- Midday: Expert panels and roundtables covering research, psychiatry, clinical implementation, practitioner education and healthcare delivery.
- Afternoon: Focused discussions on regulation, biotechnology, investment, ethics, governance and the future of psychedelic medicine.
- Late Afternoon: Closing discussions and networking.
20 MARCH EVENING — THE PRS27 VIP DINNER
An exclusive evening dinner for VIP delegates, speakers and invited guests. The VIP dinner provides an opportunity to continue the conversations from the symposium in a more intimate setting, bringing together senior clinicians, researchers, investors, healthcare leaders, founders and industry representatives. VIP places are limited.
Programme subject to change.
VIP EXPERIENCE
Go beyond the symposium.
The VIP ticket is designed for senior professionals, investors, executives and delegates who want to maximise their access to the PRS27 network. VIP delegates receive full access to the main symposium plus invitations to exclusive networking opportunities and the PRS27 VIP dinner on the evening of 20 March.
Full Symposium Access
Priority access to all PRS27 sessions and programming on 20 March.
Opening Networking Event
Join fellow delegates, speakers and industry leaders at the 19 March opening networking event.
VIP Dinner — 20 March Evening
An exclusive evening dinner for VIP delegates, speakers and invited guests. Continue the conversation in a more intimate setting with senior clinicians, researchers, investors and industry leaders.
NETWORKING
The people in the room matter.
PRS27 is deliberately designed to create opportunities for genuine professional connection across both days. Delegates will have opportunities to meet clinical leaders, researchers, psychiatrists, psychologists, healthcare operators, biotech executives, investors, founders, educators, policy professionals and industry leaders.
OPENING NETWORKING EVENT — 19 MARCH
An opportunity to meet fellow delegates, speakers, clinicians, researchers, investors, healthcare leaders and industry representatives before the main symposium begins. A relaxed start to the PRS27 experience.
NETWORKING DRINKS — 20 MARCH, 4:00–5:00 PM
Connect with speakers, delegates and industry leaders following the formal programme on the main symposium day.
VIP DINNER — 20 MARCH EVENING
An exclusive evening dinner for VIP delegates, speakers and invited guests. Continue the conversation in a more intimate setting with senior clinicians, researchers, investors and industry leaders. VIP places are limited.
SPEAKERS
The people shaping what comes next.
PRS27 will bring together leading voices from clinical practice, psychiatry, psychology, research, education, healthcare, biotechnology, investment, regulation and industry. The speaker programme will continue to be announced as speakers are confirmed.
Dr Chris Corney
CEO Hollograf
Gary Mackenzie
Editor, Psychedelics.meda - Executive Producer PRS27.
Dr Jules Dodermaide
Psychiatrist, Authorised Prescriber
Dr Mitch Mckean
Title, Organisation
Dr Lani
Title, Organisation
Professor Kylie O'Brien
Title, Organisation
PRESENTED BY
PRS27 — Australia's Psychedelic Medicine & Mental Health Symposium is produced and presented by Psychedelics.media.
SPONSORS & PARTNERS
PRS27 brings together organisations supporting the development of psychedelic medicine, mental healthcare, clinical research, education, biotechnology and healthcare innovation.
TITLE SPONSOR
$25,000
STRATEGIC PARTNER
$15,000
INDUSTRY SPONSORS
$10,000
Limited sponsorship opportunities are available. Partnership opportunities can include brand visibility, speaking and panel participation, booth exhibition and networking opportunities, thought leadership and direct engagement with senior VIP delegates.
WHY PARTNER WITH PRS27?
Psychedelic medicine is developing rapidly. PRS27 provides organisations with a direct opportunity to engage with the professionals, decision-makers and emerging leaders shaping the sector.
Direct Access to a Senior Professional Audience
Brand Positioning Within an Emerging Healthcare Sector
Thought Leadership Opportunities
Speaking and Panel Opportunities
Clinical and Industry Networking
Relationship Development
Access to Emerging Commercial and Healthcare Opportunities
FREQUENTLY ASKED QUESTIONS
Find answers to common questions about PRS27.
Q: Is PRS27 a research conference?
A: No. Research and clinical evidence are important parts of PRS27, but the symposium takes a much broader view — exploring the entire ecosystem required for psychedelic medicine to develop, including clinical practice, psychiatry, practitioner education, regulation, healthcare delivery, biotechnology, investment, ethics, governance and industry.
Q: Who is PRS27 for?
A: PRS27 is designed for professionals working in or around psychedelic medicine and mental healthcare, including psychiatrists, psychologists, researchers, clinicians, healthcare operators, educators, investors, biotechnology companies, policymakers, regulators and industry leaders.
Q: Do I need to be a psychedelic specialist to attend?
A: No. PRS27 is designed for people already working in the field as well as professionals seeking to understand how psychedelic medicine may develop and intersect with mainstream mental healthcare.
Q: Will there be international speakers?
A: Yes. PRS27 will bring together Australian and international perspectives as the symposium examines the development of psychedelic medicine both locally and globally.
Q: Is PRS27 suitable for psychiatrists?
A: Yes. Psychiatry is a central component of the symposium, alongside clinical implementation, research, regulation, training and the broader future of mental healthcare.
Q: Will there be opportunities to network?
A: Yes. Networking is a core part of PRS27, with dedicated networking opportunities throughout the symposium, networking drinks and an exclusive VIP dinner.
Q: Where is PRS27 being held?
A: Melbourne, Australia. Full venue and location information will be announced as the event programme develops.
Q: When is PRS27?
A: 19–20 March 2027.
Q: How much are tickets?
A: Early Bird: Standard $495 AUD, Student $295 AUD, VIP $995 AUD. Standard pricing is $695 AUD, student $395 AUD and VIP $1,495 AUD.
REGISTER FOR PRS27
Be part of the conversation shaping the future of psychedelic medicine.
The psychedelic medicine sector is moving rapidly. The next stage will not be defined by research alone. It will be defined by how effectively the field translates evidence into clinical practice, develops its workforce, builds appropriate healthcare systems, establishes responsible regulation and creates sustainable models for innovation and investment. PRS27 brings the people working on those challenges together.
MELBOURNE
19–20 MARCH 2027
Australia's Psychedelic Medicine & Mental Health Symposium
PRS27 is produced by Psychedelics.media
Clinical Practice | Psychiatry | Research | Education | Regulation | Healthcare | Biotechnology | Investment | Ethics | Governance
© 2027 PRS27. All rights reserved.
Psychedelic Roundtable Symposium